53
Participants
Start Date
September 23, 2022
Primary Completion Date
April 18, 2024
Study Completion Date
April 18, 2024
Efgartigimod
Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
Placebo
"Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively"
Johns Hopkins University, Baltimore
Vandetbilt University Medical Center / Clinical Research Center, Nashville
Case Western Reserve University, Cleveland
Northshore University Health System, Glenview
Texas Institute of Cardiology, McKinney
Apex Trials Croup, LLC, Fort Worth
Pioneer Clinical Research, Rosharon
Metrodora Institute, West Valley City
University of California, San Diego Sulpizio Cardiovascular Center, La Jolla
Stanford Movement Disorder Center, Palo Alto
Harvard Medical School, Brigham and Women's Hospital, Boston
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
argenx
INDUSTRY